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SUMMARY

Genome rearrangements, a hallmark of cancer, can
result in gene fusions with oncogenic properties.
Using DNA paired-end-tag (DNA-PET) whole-genome
sequencing, we analyzed 15 gastric cancers (GCs)
from Southeast Asians. Rearrangements were enriched in open chromatin and shaped by chromatin
structure. We identified seven rearrangement hot
spots and 136 gene fusions. In three out of 100 GC
cases, we found recurrent fusions between CLDN18,
a tight junction gene, and ARHGAP26, a gene encoding a RHOA inhibitor. Epithelial cell lines expressing
CLDN18-ARHGAP26 displayed a dramatic loss of
epithelial phenotype and long protrusions indicative
of epithelial-mesenchymal transition (EMT). Fusionpositive cell lines showed impaired barrier properties,
reduced cell-cell and cell-extracellular matrix adhe272 Cell Reports 12, 272–285, July 14, 2015 ª2015 The Authors

sion, retarded wound healing, and inhibition of
RHOA. Gain of invasion was seen in cancer cell lines
expressing the fusion. Thus, CLDN18-ARHGAP26
mediates epithelial disintegration, possibly leading
to stomach H+ leakage, and the fusion might contribute to invasiveness once a cell is transformed.
INTRODUCTION
Worldwide, nearly one million new gastric cancer (GC) cases
were diagnosed and more than 700,000 deaths occurred in
2008 (Jemal et al., 2011). More than 70% new GC cases and
deaths came from developing countries, with the highest incidence in Eastern Asia (Jemal et al., 2011). Most GCs are diagnosed at an advanced stage, which limits the current treatment
strategies with the overall 5-year survival rate for distant or metastatic disease of 3% (Janjigian and Kelsen, 2013). On the
molecular level, GC is heterogeneous and only the amplified

Figure 1. Characteristics of Somatic SVs
Identified by DNA-PET in GC
(A) SV filtering procedure for GC patient 125 is
shown. SVs are plotted by Circos (Krzywinski
et al., 2009) across the human genome arranged
as a circle with the copy number in the outer ring
(copy number > 2.8 is shown in red; copy number < 1.5 is shown in blue), followed by deletion
(blue), tandem duplications (red), inversions
(green), and unpaired inversions (purple), and in
the inner ring, inter-chromosomal isolated translocations (orange). SVs identified in the blood of
patient 125 (middle) were subtracted from SVs
identified in gastric tumor of patient 125 (left), resulting in the somatically acquired SVs specific for
the tumor (right). Circos plots of all 15 GCs can be
found in Figure S1.
(B) Distribution of somatic and germline SVs of
15 GCs.
(C) Proportion of somatic SVs and germline SVs in
15 GCs. SV counts are shown on top.
(D) Composition of somatic SVs in GC compared
with germline SVs. SV counts are shown on top.
(E) Comparison of somatic SV compositions of GC
with reported somatic SVs for pancreatic cancer
(Campbell et al., 2010), breast cancer (Stephens
et al., 2009), and prostate cancer (Berger et al.,
2011). SVs were reduced to four categories to
allow comparison.

ERBB2 is a therapeutic target (Janjigian and Kelsen, 2013).
Therefore, identifying additional molecular biomarkers in GC
genomes will potentially result in early diagnosis and new treatment strategies. Whereas recent whole-genome- and exomesequencing studies have identified recurrently mutated genes
(Kakiuchi et al., 2014; Nagarajan et al., 2012; Wang et al.,
2011, 2014; Zang et al., 2012), genome rearrangements in GC
have not been studied in great detail. Genomic rearrangements
can have dramatic impact on gene function by amplification,
deletion, or gene disruption and can create fusion gene proteins
with new functions or locations. There is still a large gap in our
understanding of the functional role of the recurrent fusion
genes and the underlying mechanisms of genomic rearrangements that create them.
In the present study, we extended our earlier analyses by
DNA paired-end-tag (DNA-PET) sequencing of 10-kb DNA

fragments (Hillmer et al., 2011; Nagarajan et al., 2012) to characterize the
genomic structural rearrangements of
15 GCs and their impact on genes and
gene fusions. We identified CLDN18ARHGAP26, CLEC16A-EMP2, SNX2PRDM6, KMT2C (MLL3)-PRKAG2, and
DUS2 (DUS2L)-PSKH1 as recurrent
fusion genes with frequencies between
2% and 5% by an extended screen.
Detailed functional evaluation suggests
that CLDN18-ARHGAP26 negatively
affects cell-cell and cell-matrix interactions and epithelial barrier function,
thereby potentially contributing to gastritis, a known risk factor
for GC.
RESULTS
SVs in GC Identified by Whole-Genome DNA-PET
Sequencing
We sequenced genomic DNA from 14 primary gastric tumors
including ten paired normal samples (clinical data in Table S1)
and GC cell line TMK1 by DNA-PET (Hillmer et al., 2011; Yao
et al., 2012). With approximately 2-fold bp coverage and 200fold physical coverage of the genome (Table S2), we identified
1,945 somatic structural variations (SVs) (Figures 1A–1C and
S1; Table S3; Supplemental Experimental Procedures and
Supplemental Results) with significant differences in SV distributions between germline and somatic SVs (p = 2.2 3 10 16; c2
Cell Reports 12, 272–285, July 14, 2015 ª2015 The Authors 273
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tests; Figure 1D), suggesting different mutational or selective
mechanisms. Compared to other cancer types that have been
analyzed for SVs in detail (Berger et al., 2011; Campbell et al.,
2010; Stephens et al., 2009), GC showed a higher proportion of
274 Cell Reports 12, 272–285, July 14, 2015 ª2015 The Authors

Figure 2. Breakpoint Features of Somatic
SVs Provide Mechanistic Insights
(A–C) Characterization of breakpoint locations of
somatic SVs in GC. Coordinates of repeats and
genes were downloaded from UCSC genome
browser (Rhead et al., 2010), and open chromatin
regions were compiled from Encyclopedia of DNA
Elements (ENCODE) (Djebali et al., 2012).
(D) Gene-involving rearrangements can have insertions of small DNA fragments originating from
one of the SV breakpoints. Arrows represent
genomic fragments. Breakpoint coordinates are
indicated, and micro-homologies are shown above
breakpoint pairs.
(E and F) Overlap of somatic SVs identified by
DNA-PET in breast cancer (BC) (n = 1,935; Hillmer
et al., 2011) and GC (n = 1,945) and germline SVs in
GC patients (n = 1,667) with long-range chromatin
interactions bound to RNA polymerase II in gastric
cancer cell line HGC27 (E; n = 7,623) and in breast
cancer cell line MCF-7 (F; n = 87,253; Li et al.,
2012). Absolute numbers are shown above bars.
Fraction of SVs overlapping with ChIA-PET interactions is calculated relative to the total number
of SVs of each data set (e.g., GC SVs). All SV/
chromatin interaction overlaps are significantly
higher than expected by chance (p < 0.001; permutation based).
(G) Example of an overlap of a somatic unpaired
inversion in GC and a chromatin interaction. Coordinates of chromosome 13 are shown on top.
UCSC gene track is displayed in green. The PET
mapping coordinates of a somatic 5.3-kb unpaired
inversion of GC tumor 133 are shown with the
upstream mapping region in red and the downstream mapping region in gray. Number in
brackets indicates number of non-redundant PET
reads connecting the two regions (cluster size).
(Bottom) Chromatin interaction is identified by
ChIA-PET in cell line HGC27. Each pink peak
represents one end of a mapped chromatin interaction, and the blue arch shows an interaction
between two breakpoint regions.

tandem duplications than prostate cancer
and more inversions than pancreatic cancer (Figure 1E), indicating that each cancer
type bears its own rearrangement pattern.
Characteristics of Somatic SVs in
GC Provide Insight into
Rearrangement Mechanisms
Both germline and somatic breakpoints
were enriched in repeat regions (p <
10 5; Figure 2A) and open chromatin domains (p < 10 21; c2 test; Figure 2B)
whereas only somatic breakpoints were
enriched in genes (p < 10 15; c2 test)
and germline breakpoints were depleted in genes (p < 10 15;
c2 test; Figure 2C). This might reflect the negative selection for
gene-disruptive rearrangements in germline and, in contrast,
the pro-cancer potential for somatic rearrangements altering

gene structures. These observations suggest that transcriptionally active parts of the genome are more prone for somatic rearrangements in GC (more details in the Supplemental Results).
We noticed in 2% of validated fusion points a characteristic
pattern where the inserted sequence originated from a locus
near the fusion point (Figure 2D; Supplemental Results). Three
of these cases created fusion genes (ARHGAP26-CLDN18,
LIFR-GATA4, and MLL3-PRKAG2). Intriguingly, the same rearrangement characteristics have been described for a translocation with the same gene, ARHGAP26, in a patient with juvenile
myelomonocytic leukemia creating a fusion with KMT2A (Borkhardt et al., 2000). The repeated observation of neighbor locus
sequence insertions at rearrangement points suggests a specific
mechanism, which might be transcription coupled.
We tested whether the rearrangement partner sites of somatic
SVs tend to be in spatial proximity within the nucleus by searching for overlap between rearrangement points of SVs and
chromatin interaction analysis by paired-end-tag (ChIA-PET)
sequencing data (Li et al., 2012). We performed ChIA-PET
sequencing for the GC cell line HGC27 and compared the
derived chromatin interactions (n = 7,623) with the SVs of the
15 GCs (1,667 germline and 1,945 somatic SVs). We found six
germline and two somatic SV overlaps, more than expected by
chance (p < 0.001; permutation based; Figures 2E and 2G; Supplemental Experimental Procedures), indicating that chromatin
interactions might contribute to the shape of germline and somatic GC SVs. We performed the same analysis with breast cancer cell line MCF-7 (87,198 chromatin interactions; Li et al.,
2012), representing another epithelial cancer, and observed
overlaps with 61 germline and 19 somatic GC SVs, respectively
(p < 0.001; permutation based). Chromatin interactions in
HGC27 overlapped better with somatic SVs in gastric than in
breast cancer, whereas chromatin interactions in MCF-7 overlapped better with somatic SVs in breast than GC (Figures 2E
and 2F), suggesting that tissue-specific chromatin interactions
can contribute to the formation of somatic SVs.
Recurrent Fusion Genes in GC
Using the somatic SVs of the 15 GCs, we were able to predict
136 fusion genes (Tables S3 and S6), validated 97 of them by
genomic PCR and Sanger sequencing, and confirmed the
expression of 44 by RT-PCR in the respective tumors (Table
S6). Fifteen expressed fusion genes were in frame. Because
constitutively active oncogenic fusion genes are usually in-frame
fusions, we focused on this category to screen an additional set
of 85 GC tumor/normal pairs by RT-PCRs and found SNX2PRDM6 in one additional tumor, CLDN18-ARHGAP26 and
DUS2L-PSKH1 in two additional tumors, MLL3-PRKAG2 in
three additional tumors, and CLEC16A-EMP2 in four additional
tumors, giving overall frequencies of 2%–5% (Figures 3A and
S2; Table S6). We performed statistical simulations to assess
the significance of such rates of recurrence (Experimental Procedures) and found that they were not expected by chance (p =
0.00472), with higher levels of significance for two rediscoveries
(p = 9.98 3 10 5) and three rediscoveries (p = 1.11 3 10 5). This
suggests that these fusion genes are not randomly created but
most likely by targeted rearrangement mechanisms and/or that
the resulting fusion genes provide selective advantages.

To explore whether the fusion genes provided selective advantages, we used a network fusion centrality analysis (Wu
et al., 2013) to predict driver fusion genes. Among the 136 fusion
genes of our study, 38 were classified as potential driver
fusion genes, including CLDN18-ARHGAP26, SNX2-PRDM6,
and MLL3-PRKAG2 (Table S7).
Further, we investigated the ratio of the discordant PETs
(dPETs) that connect the fusion gene creating rearrangement
points versus concordant paired-end tags (cPETs) that cover
the fusion gene regions in the wild-type configuration. If the
fusion gene rearrangements are early rearrangements, it is
expected that such rearrangements can be observed from
more cells and a relatively high dPET/cPET ratio from these rearrangements should be found. We compared the dPET/cPET
ratio of the fusion gene rearrangements with all other somatic rearrangements. The fusion gene rearrangement point of CLDN18ARHGAP26, MLL3-PRKAG2, and SNX2-PRDM6 had higher
dPET/cPET ratios than the median of the ratios for the somatic
rearrangements of the samples in which they were discovered
(tumor 136, TMK1, and tumor 125, respectively; data not shown),
suggesting that the fusion genes are created by relatively early
rearrangements.
We tested for the impact of the recurrent fusion genes on proliferation by knocking down MLL3-PRKAG2 and DUS2L-PSKH1
in TMK1 and establishing stable cell lines expressing CLDN18ARHGAP26, CLEC16A-EMP2, and SNX2-PRDM6. We found evidence for proliferative supporting function for MLL3-PRKAG2
and CLEC16A-EMP2 (Figure S3; Supplemental Results; see
below). For rearrangement hot spots and global impact of somatic SVs on genes, see Tables S4 and S5 and the Supplemental
Results.
Phenotypic Changes by CLDN18-ARHGAP26 Are Not a
Result of Classical Epithelial-Mesenchymal Transition
Because CLDN18 is an essential tight junction (TJ) component in
the stomach with its deficiency causing paracellular H+ leakage
(Hayashi et al., 2012) and ARHGAP26 likely affects adhesion of
cells to the extracellular matrix (ECM) through its regulation of
RHOA, a gene recently shown to be mutated in GC (Kakiuchi
et al., 2014; Wang et al., 2014), we performed a deeper analysis
of CLDN18-ARHGAP26. On the genomic level, we validated the
CLDN18-ARHGAP26 rearrangement in tumors 136 and 07K611
by fluorescence in situ hybridization (FISH) (Figures 3B and S2K)
and PCR/Sanger sequencing (Figure 3C). Using custom capture
sequencing, we verified the genomic fusion point on chromosome 3 in tumor 07K611 to be 2,342 bp downstream of
CLDN18 (Figures 3A and S2A). Array expression analysis of
tumor 136 suggested that it belongs to the microsatellite stable/TP53 expression profile class defined recently (Cristescu
et al., 2015; data not shown).
In all three tumors with CLDN18-ARHGAP26 fusions, the transcripts were joined by a cryptic splice site within the coding region of exon 5 of CLDN18 and the regular splice site of exon
12 of ARHGAP26 (Figures 3D and 3F). CLDN18-ARHGAP26
encodes a 75.6-kDa fusion protein containing all four transmembrane domains of CLDN18 and the RhoGAP domain of ARHGAP26 (Figure 3E) but lacking the C-terminal PDZ-binding motif
of CLDN18 that mediates interactions with TJ proteins (TJP1,
Cell Reports 12, 272–285, July 14, 2015 ª2015 The Authors 275
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Figure 3. Recurrent CLDN18-ARHGAP26 InFrame Fusions in GC

B

(A) RefSeq gene track (top), copy number of tumor
136 by DNA-PET sequencing (middle), and PET
mapping of a somatic balanced translocation with
breakpoints in CLDN18 and ARHGAP26 in tumor
136 (bottom). Numbers of fused exons are shown
in red. Mapping regions of DNA-PET clusters are
shown by red and gray arrow heads with cluster
size in brackets and dashed lines at Sanger
sequencing validated breakpoint coordinates in
squared brackets. Location of genomic breakpoints of tumor 07K611 (chr3:139,237,526 and
chr5:142,309,897) are indicated by green arrows.
(B) Validation of genomic rearrangement by FISH of
tumor 136.
(C) RT-PCRs of tumor/normal pairs of two gastric
cancers with CLDN18-ARHGAP26 fusions. RTPCRs for b-actin (ACTB) serve as positive control.
M, marker; N, normal gastric tissue; T, gastric
tumor.
(D) Cryptic splice site in the coding region of exon 5
of CLDN18 results in the extension of the open
reading frame into ARHGAP26. Sequences of the
fusion transcript are highlighted in red.
(E) Protein domain ideogram of CLDN18-ARHGAP26. TM, transmembrane.
(F) Sanger sequencing chromatogram of RT-PCR
of CLDN18-ARHGAP26 of tumor 136. Fusion point
between CLDN18 and ARHGAP26 is indicated by
red dashed line.
(G) qRT-PCR for the CLDN18-ARHGAP26 fusion
transcript in MCF10A non-transfected cells and
stable cell lines with CLDN18-ARHGAP26-expressing vector.
Data are presented as mean ± SD (G).
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TJP2, and TJP3). ARHGAP26 (GRAF1) binds to focal adhesion
kinase (FAK or PTK2), which modulates cell growth, proliferation,
survival, adhesion, and migration (Doherty and Lundmark, 2009).
ARHGAP26 can also negatively regulate the small GTP-binding
protein RHOA, which is well known for its growth-promoting effect in RAS-mediated malignant transformation (Hildebrand
et al., 1996; Qian et al., 2010).
CLDN18 protein was observed in the plasma membrane of
epithelial cells lining the gastric pit region and at the base of
the gastric glands as previously reported in normal human stomach specimens (Sahin et al., 2008; Figure 4A). ARHGAP26 was
previously detected on pleiomorphic tubular and punctate membrane structures in HeLa cells (Lundmark et al., 2008). We
observed ARHGAP26 in normal stomach on vesicular structures
276 Cell Reports 12, 272–285, July 14, 2015 ª2015 The Authors

restricted to parietal cells that specifically
express the H+/K+ ATPase or ‘‘proton
pump’’ (Figures 4B and S4A). Stomach
tumor specimens of patient 136, with a
cancer stage of 4 and one metastasis, expressing CLDN18-ARHGAP26, showed
a diffused structure, characteristic for
late-stage tumors, with some regions
lacking E-cadherin (CDH1) staining (Figures 4A and 4B). CLDN18-ARHGAP26
was present in both CDH1-positive and negative cells; with the
CDH1-negative cells showing mesenchymal features such as
elongated and spindled morphology (Figures 4A and 4B).
To understand the effect of the fusion protein to changes on
epithelial integrity, we stably expressed CLDN18, ARHGAP26,
or CLDN18-ARHGAP26 in the non-transformed epithelial
cell lines MCF10A (human breast; Figures 3G and S4B) and
MDCK (canine kidney) and in the transformed cancer cell
lines HGC27 (gastric) and HeLa (cervical cancer). Viewed by
phase contrast, control and CLDN18 in MCF10A and MDCK
cell cultures, respectively, showed the characteristic epithelial
morphology (Figures 4C and S4C). Whereas ARHGAP26-expressing MCF10A and MDCK cells were more spindle shaped
and had short protrusions as previously reported (Taylor et al.,

A

B

C

D

E

F

Figure 4. CLDN18-ARHGAP26-Fusion-Expressing Patient Specimen and MCF10A Cells Exhibit Loss of Epithelial Phenotype
(A and B) CLDN18 (A) and ARHGAP26 (B) expression in normal and gastric tumor patient specimens. Human normal (top) and tumor (bottom) stomach sections
were stained with DAPI and antibodies to CDH1 as well as CLDN18 and ARHGAP26, respectively, for immunofluorescence analysis.
(C) CLDN18-ARHGAP26-fusion-expressing MCF10A cells display fusiform and protrusive morphology. Phase contrast images of non-transfected (NT) and
stable lines expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 in MCF10A cells obtained at sub-confluent levels.
(D) qPCR of EMT markers in MCF10A cells stably expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26, respectively.
(E) Western blot analysis of NT HGC27 and HeLa cells and stables expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 gene by immunoblotting for
indicated proteins. GAPDH is used as loading control.
(F) Cell aggregation assay. MCF10A NT and stable lines expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 were plated as hanging drops, and phase
contrast images were obtained the next day.
Data are presented as mean ± SD (D). The scale bars in (A) and (B) represent 30 mm.
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Figure 5. CLDN18-ARHGAP26 Expression Results in Reduced Cell-ECM Adhesion
(A) (Top) Cell-ECM adhesion assay. MCF10A stable lines expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 were seeded on untreated plates, and
phase contrast images were obtained 2 hr after seeding. MCF10A NT cells were used as control. (Bottom) Quantification of cells that adhered to untreated
collagen type I and fibronectin-treated surfaces is shown. The proportion of cells that adhered was quantified relative to NT MCF10A cells (100%).
(B) MCF10A stable lines expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 were fixed and immunostained with antibodies to activated PTK2 and HA
or GFP.
(C) Absence of PXN in free edges in CLDN18-ARHGAP26-expressing MCF10A cells. MCF10A stable lines expressing CLDN18, ARHGAP26, and CLDN18ARHGAP26 were fixed and immunostained with antibodies to PXN and HA or GFP.

(legend continued on next page)
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1999), CLDN18-ARHGAP26 expression in both cell lines displayed a dramatic loss of epithelial phenotype and long protrusions, suggestive of epithelial-mesenchymal transition (EMT)
(Figures 4C and S4C). Cell protrusion phenotype was also
observed in transformed HGC27 and HeLa cells (Figures S4D
and S4E).
To evaluate whether the phenotypic changes induced by
CLDN18-ARHGAP26 reflected a classical EMT, we investigated
the expression of various EMT markers using qPCR. Whereas
CDH1 mRNA levels were reduced for CLDN18-ARHGAP26-expressing MCF10A cells, other EMT markers were unchanged
or reduced, indicating that the morphological changes were
not based on classical EMT (Figure 4D). In MDCK cells, CDH1
levels were unchanged and mRNA of the master EMT regulators
SNAI1 and SNAI2 (SLUG) were decreased (Figure S4F). MDCKCLDN18-ARHGAP26 showed a 5.2-fold increase in matrix metalloproteinase 2 (MMP2) mRNA levels relative to control MDCK
cells (Figure S4F), suggesting changes in ECM adhesion induced
by the fusion gene (Sahin et al., 2008).
Interestingly, expression of CLDN18, but not the fusion protein,
downregulated N-cadherin (CDH2) and b-catenin (CTNNB1)
expression in transformed HGC27 and HeLa cells (Figure 4E),
suggesting that CLDN18 can reverse the switch from an epithelial
to a mesenchymal cadherin observed during EMT and suppress
Wnt signaling, respectively. Wnt signaling is hyperactivated in
many cancers, and CDH2 expression activates AKT signaling
(Tran et al., 2002), which is hyperactivated in many tumors.
Although CTNNB1 and CDH2 were reduced in both cancer cell
lines, pAKT1 protein levels, as well as those of the downstream
effector p21-activated kinase (PAK1), were predominantly reduced in HeLa cells overexpressing CLDN18 as compared to
controls (Figure 4E). This might suggest a role for CLDN18 as a
tumor suppressor by dampening AKT1 and Wnt signaling.
CLDN18-ARHGAP26 Reduces Cell-ECM Adhesion
ARHGAP26 likely affects adhesion of cells to the ECM through its
interaction with PTK2 (FAK) and its regulation of RHOA, which in
turn regulates focal adhesions (Taylor et al., 1999). Cell aggregation assays indicated poor aggregation for MCF10A-CLDN18ARHGAP26 cells (Figure 4F), suggesting that indeed the fusion
gene causes epithelial changes that affect cell-cell interaction.
Similar results were obtained with MDCK, HGC27, and HeLa
cells (Figures S4H–S4J). Adhesion assays showed that control
and MCF10A-CLDN18 cells attached and spread on either
untreated or ECM-coated surfaces. Not only did ARHGAP26and, even more so, CLDN18-ARHGAP26-expressing cells atta-

ch less efficiently to the surfaces (Figure 5A), but the cells that did
attach were still rounded up 2 hr after seeding (Figure 5A),
showing that the fusion gene potentiates the effect of ARHGAP26 and strongly affects cell-ECM adhesive properties.
Similar results were obtained in MDCK, HGC27, and HeLa cells
(Figures S5A–S5F).
The SH3 domain of ARHGAP26, present in the fusion protein,
binds to the focal adhesion molecules, PTK2 and PXN (paxillin)
(Doherty et al., 2011). We therefore examined the effect of
CLDN18-ARHGAP26 expression on focal adhesion proteins.
pPTK2 and PXN were detected at the free edge of MCF10ACLDN18. These molecules were reduced in MCF10A-ARHGAP26
but were absent from this location in MCF10A-CLDN18-ARHGAP26 cells (Figures 5B and 5C). Western blot analysis for adhesion molecules associated with ARHGAP26 or focal adhesion
complex proteins showed reduced levels for integrin-linked
kinase (ILK), Talin 1 (TLN1), and PXN in MCF10A-ARHGAP26
and more pronounced so in MCF10A-CLDN18-ARHGAP26 cells
(Figure 5D). Significant decrease in levels of ILK and Talin 2 (TLN2)
transcripts was observed in MCF10A-ARHGAP26 and MCF10ACLDN18-ARHGAP26 cells by qPCR (Figure 5E). Changes in localization of focal adhesion molecules at free edges (pPTK2 and
PXN) and protein expression patterns of focal adhesion components were also observed in MDCK, HGC27, and HeLa cells, indicating poor ECM adhesion of CLDN18-ARHGAP26-expressing
cells (Figures S5G–S5I).
In addition to the cytoplasmic components of focal adhesions, we analyzed mRNA levels of integrin family members,
which directly interact with the ECM components (Calderwood,
2004). Consistent with the poor attachment of MCF10ACLDN18-ARHGAP26 cells on collagen-coated surfaces (Figure 5A), these cells expressed reduced levels of integrin b3
(ITGB3), integrin b8 (ITGB8), and integrin aV (ITGAV) (Figure 5F).
A decrease in transcript levels of integrin subunits, in particular integrin b1 (ITGB1), integrin a3 (ITGA3), and integrin a5
(ITGA5), was observed in MDCK-CLDN18-ARHGAP26 cells (Figure S5J). In summary, overexpression of ARHGAP26 and even
more pronounced of the fusion gene disrupt ECM adhesion.
The Epithelial Barrier Promoted by CLDN18 Is
Compromised by CLDN18-ARHGAP26
Claudins are critical components of the paracellular epithelial barrier, including the protection of the gastric tissue from the acidic
milieu in the lumen (Davenport, 1972a, 1972b, 1975). Alterations
of this barrier function might cause chronic inflammation (Jovov
et al., 2007; Sanders et al., 1985), a risk factor for the development

(D) Western blot analysis of focal adhesion molecule levels in MCF10A NT and stable lines expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26. GAPDH
was used as loading control.
(E) Reduced levels of focal adhesion molecules in CLDN18-ARHGAP26-expressing MCF10A. qPCR analysis of MCF10A stable lines expressing CLDN18,
ARHGAP26, and CLDN18-ARHGAP26 was performed for focal adhesion molecules. Fold changes were calculated relative to MCF10A NT cells.
(F) Reduction in integrin subunit levels in CLDN18-ARHGAP26-expressing MCF10A. qPCR analysis of MCF10A-CLDN18, -ARHGAP26, and -CLDN18-ARHGAP26 stables was performed for integrin subunits. Fold changes were calculated relative to MCF10A NT cells.
(G) MDCK stable lines expressing CLDN18, CLDN18 with inactivated C-terminal PDZ-binding motif (CLDN18DP), ARHGAP26, CLDN18-ARHGAP26, and NT
MDCK cells were seeded on Transwell inserts, and TER values were measured over a period of 48 hr. Empty Transwell inserts were used as negative control.
Experiments were performed in duplicate.
(H) Phase contrast images of NT MDCK and stables expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 at confluent levels.
Data are presented as mean ± SD (A, E, and F). Scale bars in (B) and (C) represent 10 mm.
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of GC (Vannella et al., 2012), prompting us to explore the role of
CLDN18 and the fusion protein in barrier formation. Overexpression of CLDN18, which is not endogenously expressed in MDCK
cells, resulted in a dramatic increase in the transepithelial electrical
resistance (TER) of MDCK-CLDN18 monolayers. Whereas ARHGAP26 had no significant effect on the TER, CLDN18-ARHGAP26
completely abolished the TER (Figure 5G). This effect did not simply reflect the lack of the C-terminal PDZ-binding motif, because a
CLDN18 construct where this C-terminal PDZ-binding motif was
inactivated (CLDN18DP) still increased the baseline TER of
MDCK cells. Phase contrast images of confluent CLDN18-ARHGAP26-fusion-expressing MDCK cells showed that these cells
failed to form tight monolayers, explaining the loss of TER (Figure 5H). Whereas expression levels and subcellular localization
of TJP1, a scaffold protein that directly links claudins to the actin
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Figure 6. CLDN18-ARHGAP26 Has a CellContext-Specific Impact on Proliferation,
Wound Closure, and Invasion
(A) Delayed cell proliferation rates in CLDN18ARHGAP26-fusion-expressing MCF10A cells.
MCF10A stable lines expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 were seeded at
800 cells in quadruplicate in 24-well plates.
MCF10A NT cells were used as control.
(B) Wound healing assay of MCF10A stable lines
expressing CLDN18, ARHGAP26, and CLDN18ARHGAP26. Phase contrast images were obtained
at the start of the experiments and at intervals.
(C) HGC27 cells stably expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 fusion gene
were seeded on Matrigel invasion chamber. NT
HGC27 cells were used as control. Cells were fixed,
washed, and stained with crystal violet to obtain
phase contrast images (left) and to quantitate (right)
the number of cells that invaded the Matrigel.
(D) HGC27 cells stably expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 were seeded on
soft agar, incubated for 1 month, imaged (left), and
counted (right). Parental lines stably transfected
with vector were used as control.
Data are presented as mean ± SD (A, C, and D).

cytoskeleton, were not altered in MDCK
cells expressing the fusion protein (Figure S5K), the expression of several other
TJ components was upregulated in
MDCK-CLDN18-ARHGAP26, possibly reflecting a compensatory mechanism
(Figure S5L).
CLDN18-ARHGAP26 Exerts CellContext-Specific Effects on Cell
Proliferation, Invasion, and
Migration
CLDN18-ARHGAP26 reduced cell proliferation in transfected MDCK, HGC27, and
HeLa cells compared to controls (Figure S6A). In MCF10A, CLDN18-ARHGAP26 cells had lower cell proliferation
compared to non-transfected and ARHGAP26 but a higher proliferation rate than MCF10A-CLDN18 cells
(Figure 6A), suggesting cell-context-specific differences. Interestingly, CLDN18-ARHGAP26 expression in the four analyzed cell
lines delayed wound closure (Figures 6B and S6B). Expression
of CLDN18-ARHGAP26 in MCF10A and MDCK cells had no effect
on invasion and anchorage-independent growth (Figures S6C and
S6D), which are features of cancer progression and metastasis.
The fusion therefore might not be considered a classical oncogenic driver and, as expected, we found independent driver mutations in the CLDN18-ARHGAP26-positive tumors (Supplemental
Results). We tested whether invasion and anchorage-independent growth were altered in cancer cell lines HGC27 and HeLa.
Two independent HGC27 and HeLa cell lines stably expressing
CLDN18-ARHGAP26 showed 300- to 600-fold and 3- to 4-fold
increase in cell invasion (Figures 6C and S6F). However,

CLDN18-ARHGAP26 in these transformed cells appeared to be
less efficient in soft agar growth assays compared to controls (Figures 6D and S6G). These findings highlight different effects of the
fusion protein on proliferation, invasion, and anchorage-independent growth in non-transformed and transformed cells and might
suggest a role of the fusion protein driving late cancer events such
as invasion.
Both ARHGAP26 and CLDN18-ARHGAP26 Inhibit RHOA
and Stress Fiber Formation
RHOA regulates many actin events like actin polymerization,
contraction, and stress fiber formation upon growth factor receptor or integrin binding to their respective ligands (Nobes
and Hall, 1995). ARHGAP26 stimulates, via its GAP domain,
the GTPase activities of CDC42 and RHOA, resulting in their
inactivation (Taylor et al., 1999). Given that the CLDN18-ARHGAP26 fusion protein retains the GAP domain of ARHGAP26, it
may still be able to inactivate RHOA. To test this, we analyzed
the effect of CLDN18-ARHGAP26 expression on stress fiber formation and the presence and subcellular localization of active
RHOA. In MCF10A, MDCK, HGC27, and HeLa cells, stable overexpression of ARHGAP26 or CLDN18-ARHGAP26 induced
cytoskeletal changes, notably a reduction in stress fibers indicative of RHOA inactivation (Figures 7A and S7A–S7C). Labeling of
stable MCF10A cell lines with an antibody that specifically recognizes activated RHOA showed reduced labeling in ARHGAP26
and even more so in CLDN18-ARHGAP26-fusion-protein-expressing cells (Figure 7B), whereas total RHOA levels remained
unchanged in ARHGAP26-expressing cells and were reduced
in fusion-expressing cells (Figures 7C and S7D). G-LISA assay
measuring levels of active RHOA further confirmed these results
(Figure 7D). These findings were also observed in MDCK cells
(Figures S7E–S7G) and suggest that the GAP domain in the
CLDN18-ARHGAP26 fusion protein retains its inhibitory activity
on RHOA and lower total RHOA levels contribute to reduced
RHOA function.
CLDN18-ARHGAP26 Fusion Protein Suppresses
Clathrin-Independent Endocytosis
ARHGAP26 has been shown to regulate, through its BAR and PH
domains, clathrin-independent endocytosis. Changes in endocytosis can affect cell surface residence time and/or degradation of
cell-ECM and cell-cell adhesion proteins as well as receptor tyrosine kinases, thereby altering cell adhesion, migration, and receptor tyrosine kinase signaling, which can drive carcinogenesis
(Mellman and Yarden, 2013). MCF10A, MDCK, HGC27, and
HeLa cells expressing the CLDN18-ARHGAP26 fusion protein
showed a significant reduction of endocytosis (Figures 7E and
S7H–S7J; Supplemental Results), consistent with the absence
of the BAR and PH domains, which are essential for the role of
ARHGAP26 in this process (Doherty et al., 2011), from the fusion
protein. A summary of the effects of CLDN18-ARHGAP26 on the
four analyzed cell lines is provided in Figure 7F.
DISCUSSION
In our study, we observed recurrent somatic SVs and recurrent
fusion genes in GC. Our simulations show that the rate of recur-

rent fusion genes could not be explained by chance, indicating
that specific rearrangements are more likely to occur than others
and/or that selective processes enrich for such rearrangements.
By comparing the somatic SVs with a genome-wide view of
chromatin interactions, we found significantly more overlaps of
rearrangement sites with chromatin interactions than expected
by chance, suggesting that the chromatin structure contributes
to recurrent fusions of distant loci in GC.
We validated 136 fusion genes, evaluated their expression and
reading frame characteristics, and identified five of these fusion
genes as recurrent by an extended screen. Our detailed analysis
of CLDN18-ARHGAP26 showed its functional properties by promoting both early cancer development and late disease progression. CLDN18 and ARHGAP26 are expressed in the gastric mucosa epithelium, where CLDN18 localizes to TJs and ARHGAP26
to punctate tubular vesicular structures of parietal epithelial
cells. In normal gastric epithelia, we observed ARHGAP26
expression to be specific to parietal cells. The CLDN18-ARHGAP26 fusion gene under the influence of CLDN18 promoter is
probably expressed in all gastric epithelial cells and not just parietal cells, introducing the functions of ARHGAP26, in particular
its RHOA GAP activity, to cell types normally not expressing this
protein. Moreover, the CLDN18-ARHGAP26 fusion gene links
functional protein domains of a regulator of RHOA to a TJ protein, resulting in altered properties. These, as well as the aberrant
localization of the GAP activity to the plasma membrane via the
four transmembrane domains of CLDN18 possibly result in
changes to cellular functions that are associated with GC.
Integrins and associated cytoplasmic focal adhesion complexes play central roles in ECM adhesion, epithelial differentiation, cell spreading, and cell migration (Lee and Gotlieb, 1999).
ARHGAP26 interacts via its SH3 domain with the focal adhesion
components PTK2 and PXN (Doherty et al., 2011). CLDN18ARHGAP26 cells showed reduced levels of integrin-focal adhesion complex constituents, which is generally associated with
decreased cell-cell and cell-ECM adhesion, and changes to
ECM integrin cytoskeletal dynamics (Priddle et al., 1998; Zhang
et al., 2008; Zheng et al., 2012) in MCF10A and MDCK cells.
ARHGAP26 negatively regulates RHOA activity via the GAP
domain (Taylor et al., 1999), which is retained in the fusion
protein. RHOA regulates many cellular processes, including
cell-ECM and cell-cell adhesion, cytoskeletal dynamics, and
vesicular trafficking, among others. Recently, recurrent mutations of RHOA have been identified in GC, resulting in proliferation gain and reduced anoikis (Kakiuchi et al., 2014; Wang et al.,
2014). In our study, we identified another mechanism of altering
RHOA function in GC. We observed lower levels of activated
RHOA (e.g., GTP-RHOA) in both ARHGAP26- and CLDN18ARHGAP26-expressing cells as compared to CLDN18-expressing MCF10A and MDCK cells. Stress fibers were no longer
observed in four cell lines expressing either ARHGAP26 or the
fusion protein, suggesting that the GAP domain of ARHGAP26,
despite being tethered to the plasma membrane domain, can still
inactivate RHOA involved in this process, although it remains
possible that this is due to the observed reduction of total
RHOA. Whereas ARHGAP26 and the fusion protein showed a
similar effect on stress fibers, it is conceivable that the two proteins show different effects in epithelial cells, where the fusion
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Figure 7. CLDN18 and ARHGAP26 Modulate Epithelial Phenotypes
(A) Actin cytoskeletal staining of MCF10A cells expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26. Cells were immunostained with HA for CLDN18- and
CLDN18-ARHGAP26-expressing cells and phalloidin conjugated with Alexa Fluor 594 fluorescence.
(B) Active RHOA immunofluorescence analysis in MCF10A NT cells and stables expressing ARHGAP26 and CLDN18-ARHGAP26. Cells were stained with an
antibody to active RHOA and DAPI.
(C) Western blot analysis of total RHOA in NT MCF10A and cells expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26. Cells were immunostained with
RHOA antibody and GAPDH.
(D) Reduced GAP activity in MCF10A stables expressing ARHGAP26 and CLDN18-ARHGAP26. The GAP activity was analyzed in a pull-down assay (G-LISA;
Cytoskeleton). The amount of endogenous active GTP-bound RHOA was determined in a 96-well plate coated with RDB domain of Rho-family effector proteins.
The GTP form of RHO from cell lysates of the different stable lines bound to the plate was determined with RHOA primary antibody and secondary antibody
conjugated to HRP. Luminescence values were calculated relative to NT MCF10A cells.
(E) Live MCF10A cells expressing CLDN18, ARHGAP26, and CLDN18-ARHGAP26 were incubated with Alexa-Fluor-594-conjugated CTxB for 15 min at 37 C
followed by washing and fixation. Cells were immunostained with HA or GFP antibody and DAPI.
(F) Summary of the functional effects of CLDN18-ARHGAP26 in MCF10A, MDCK, HGC27, and HeLa.
Data are presented as mean ± SD (D). Scale bars in (A), (B), and (E) represent 10 mm.
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protein may mediate a localized inactivation of RHOA at junctional adhesion complexes and thereby affect the cortical actin
cytoskeleton and cell-cell adhesion. Indeed, the epithelial
morphology of ARHGAP26-expressing cells is less compromised than that of cells expressing the fusion. Another difference
between ARHGAP26 and the fusion may result from the observation that GAP activity of oligophrenin-1 (OPHN1), like ARHGAP26 a member of the GRAF family, may be regulated by intramolecular interactions involving the N-terminal BAR and PH
domains (Elvers et al., 2012). Because these domains are
missing from the fusion protein, the GAP activity may no longer
be regulated in the fusion protein. The BAR and PH domains
are also required for the role of ARHGAP26 in clathrin-independent endocytosis (Doherty et al., 2011). Receptor tyrosine kinases can be endocytosed by both clathrin-dependent and independent pathways. Hence, disturbances in endocytic
trafficking, as observed in cells overexpressing the fusion, could
influence receptor tyrosine kinase signaling.
Isoform 2 of CLDN18 is stomach specific and a component of
the paracellular barrier to hydrochloric acid (Hayashi et al., 2012).
Cldn18 / mice present with paracellular leakage of luminal H+,
accompanied by inflammation and atrophic gastritis (Hayashi
et al., 2012). Although MDCK-ARHGAP26 showed a similar
TER as control cells, barrier function was abolished in cells expressing the fusion. In addition, the GAP domain linked to
CLDN18 could lead to a localized junctional inactivation of
RHOA, affecting the cortical actin at epithelial junctions.
Whether CLDN18-ARHGAP26 directly affects the intactness
of the paracellular barrier by interfering with the function of
CLDN18 or the localized inactivation of RHOA at junctions or
indirectly by weakening cell-ECM, cell-cell adhesion (Arnold
et al., 2013; Ma et al., 2013), or cytoskeletal alterations, the scenario results in an increased chronic paracellular H+ permeability, which is associated with acute and atrophic gastritis, a
risk factor for GC. Coupled with poor wound healing, damaged
epithelial cells may not be actively replaced, resulting in gaps
that enhance tissue damage, eventually leading to GC. Once
the CLDN18-ARHGAP26-expressing cells become cancerous,
they develop an invasive tendency, which is crucial to cancer
progression.
EXPERIMENTAL PROCEDURES
Clinical Tumor Samples
Patient samples and clinical information were obtained from patients who had
undergone surgery for GC at the National University Hospital, Singapore, and
Tan Tock Seng Hospital, Singapore. Informed consent was obtained from all
subjects, and the study was approved by the Institutional Review Board of
the National University of Singapore (reference code 05-145) as well as the National Healthcare Group Domain Specific Review Board (reference code 2005/
00440).
DNA/RNA Extraction from Samples
Genomic DNA and total RNA extraction from tissue samples was performed
using Allprep DNA/RNA Mini Kit (QIAGEN). Genomic DNA was extracted
from blood samples with Blood & Cell Culture DNA kit (QIAGEN).
Antibodies and Reagents
Primary and secondary commercial antibodies and reagents are described in
the Supplemental Experimental Procedures.

Cell Culture Conditions and Transfections
MCF10A, MDCK, HeLa, HGC27, and TMK1 cell lines were cultured according
to standard conditions. Transient and stable transfection experiments of
MDCK, HGC27, and HeLa were carried out using JetPrimePolyPlus transfection kit according to manufacturer’s instructions. Stable transfectants were
generated with G418 selection as outlined in previous protocol (Kausalya
et al., 2001).
DNA-PET Libraries Construction, Sequencing, Mapping, and Data
Analysis
DNA-PET library construction of 10-kb fragments of genomic DNA,
sequencing, mapping, and data analysis were performed as described in
Hillmer et al. (2011) with refined bioinformatics filtering as described in Nagarajan et al. (2012). The short reads were aligned to the NCBI human reference genome build 36.3 (hg18) using Bioscope (Life Technologies). DNA-PET
data of TMK1 and tumors 17, 26, 28, and 38 have been described previously
(Hillmer et al., 2011; GEO:GSE26954) and of tumors 82 and 92 (Nagarajan
et al., 2012; NCBI GEO: GSE30833). The SOLiD sequencing data of the eight
additional tumor/normal pairs, the ChIA-PET-sequencing data of HGC27,
and the exome sequencing data of tumors 136, 07K611, and 05/0304 can
be accessed at NCBI’s Sequence Read Archive (SRA): SRP035443. Procedures for the identification of recurrent genomic breakpoints of CLDN18ARHGAP26, filtering of germline SVs in cancer genomes, and breakpoint
distribution analyses are described in the Supplemental Experimental
Procedures.
HGC27/MCF-7 RNA Polymerase II ChIA-PET and GC DNA-PET
Comparison
To investigate whether the two partner sites of germline and somatic SVs of our
study were enriched for loci that are in proximity of each other in the nucleus,
we tested for overlap of SVs with genome-wide chromatin interaction data sets
derived from ChIA-PET sequencing of HGC27 and further of the breast cancer
cell line MCF-7 with the rationale that some chromatin interactions might be
conserved across different cell types. For HGC27 ChIA-PET description and
further details, see the Supplemental Experimental Procedures.
Driver Fusion Gene Prediction
The potential for driver fusion genes was predicted by using the tool as
described (Wu et al., 2013), and the threshold value 0.37 was set for identifying
the potential fusion drivers.
In-Frame Fusion Gene Confirmation and Screening by RT-PCR
One microgram of total RNA was reverse transcribed to cDNA using SuperScript III First-Strand Synthesis System for RT-PCR (Life Technologies)
according to the manufacturer’s instruction. PCR was done with JumpStart
REDAccuTaq LA DNA Polymerase (Sigma-Aldrich).
Generation of Cell Lines
The pMXs-Puro retroviral vectors containing the particular fusion genes were
co-transfected with pVSVG (pseudotyping construct) into GP2-293 cells using
Lipofectamine 2000 to produce virus. HGC27, HeLa, and MCF10A cells were
then infected with the viral supernatant containing expression constructs. Stable transfectants were obtained and maintained under selection pressure by
puromycin dihydrochloride (Sigma; P9620). Viral transfection was used to
establish all cell lines except CLDN18, ARHGAP26, and CLDN18-ARHGAP26
in MDCK, HGC27, and HeLa, which were transfected by Lipofectamine 2000
(Life Technologies). Under selection conditions, clones were picked and
maintained.
Cell Aggregation, Cell Adhesion, and Wound Healing Assays
For cell aggregation assay, 20 ml of 1.2 3 106/ml cells were plated on tissue culture dishes as hanging drops and phase contrast images were obtained the
next day using Nikon Eclipse TE2000-S. For cell adhesion assay, detailed information is provided in the Supplemental Experimental Procedures. For
wound healing assay, 70 ml of 7 3 105 cells/ml were plated on culture insert
in m-Dish 35 mm (Ibidi). Prior to seeding, the m-Dish plates were treated with
collagen type 1. The following day, the insert was peeled off to create a wound
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and migration was imaged with Nikon Eclipse TE2000 until closure of the
wound.
Cell Proliferation Assay
Eight hundred cells were seeded in quadruplicates for each condition in 24well plates, and readings were taken according to manufacturer’s instructions
(Cell Proliferation Reagent WST-1; Roche) for 7 days. Absorbance was
measured using Infinite M200 Quad4 Monochromator (Tecan) at 450 nm using
a reference wavelength of 650 nm.
Cell Invasion Migration Assay
5 3 104 stably transfected cells in RPMI serum-free media were plated into the
Biocoat Matrigel invasion chamber according to manufacturer’s instructions
(Corning) with 5% FBS in media added as chemoattractant to the wells of
the Matrigel invasion chamber for 24 hr. Further detail is provided in the Supplemental Experimental Procedures.
TER Analysis
2 3 105 stably transfected MDCK cells were seeded on 12-mm Transwell inserts (Corning) to obtain a polarized monolayer. The next day, the inserts
were placed in CellZcope (nanoAnalytics) for TER measurements.
Soft Agar Colony Formation Assay
Five thousand cells of stable cell lines were added to 2 ml soft agar (0.35%
Noble agar and 23 FBS media) and plated onto solidified base layers (0.7%
Noble agar with 23 FBS) with triplicates set up for each experiment. Colonies
were counted 2 to 4 weeks later.
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